XSHG
600713
Market cap979mUSD
Oct 09, Last price
5.14CNY
1D
2.59%
1Q
0.98%
Jan 2017
-35.35%
Name
NanJing Medical Company Limited
Chart & performance
P/E
10.76
P/S
0.12
EPS
0.48
Div yield, %
3.39%
Shrs. gr., 5y
7.06%
Rev. gr., 5y
6.66%
Revenues
54.96b
+2.36%
Net income
625m
+9.50%
CFO
92m
-95.70%
Dividend
Sep 17, 20260.09 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1951 and headquartered in Nanjing, China, NanJing Pharmaceutical Company Limited specializes in the nationwide wholesale and retail distribution of pharmaceutical products. The company oversees a substantial network comprising approximately 510 physical pharmacy outlets, alongside an active e-commerce platform for online sales.
Key people
Jian Sun
Finance Director, Chief Accounting Officer · since 2012
Qiu Shuang Wang
Vice President
Ningju Xu
Vice President, Chief Audit Officer · since 2012
Yao Wang
Director · since 2004
Jinping Yang
Director · since 2004
Independent Director · since 2008
Wenzhang Ji
Independent Director · since 2011
Independent Director · since 2011
Headquarters & legal address
南京市雨花台区宁双路19号云密城A幢
南京市, JS 100000
CN
南京市, JS 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||